SG Americas Securities
AKBA icon

SG Americas Securities’s Akebia Therapeutics AKBA Stock Holding History

SG Americas Securities’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$102K Sell
73,069
-100,432
-58% -$138K ﹤0.01% 2929
2025
Q4 		$279K Buy
173,501
+57,108
+49% +$120K ﹤0.01% 2788
2025
Q3 		$318K Buy
+116,393
New +$387K ﹤0.01% 2446
2025
Q2 		– Sell
-89,023
Closed -$171K – 2896
2025
Q1 		$171K Sell
89,023
-27,748
-24% -$56.6K ﹤0.01% 2642
2024
Q4 		$222K Buy
116,771
+44,806
+62% +$77.8K ﹤0.01% 2056
2024
Q3 		$95K Buy
71,965
+38,821
+117% +$51.8K ﹤0.01% 3092
2024
Q2 		$34K Buy
+33,144
New +$41K ﹤0.01% 2730
2022
Q1 		– Sell
-43,176
Closed -$98K – 2924
2021
Q4 		$98K Sell
43,176
-68,084
-61% -$186K ﹤0.01% 3091
2021
Q3 		$320K Buy
111,260
+98,423
+767% +$281K ﹤0.01% 2880
2021
Q2 		$49K Sell
12,837
-18,080
-58% -$60.9K ﹤0.01% 2740
2021
Q1 		$105K Buy
30,917
+12,421
+67% +$44.7K ﹤0.01% 3054
2020
Q4 		$52K Sell
18,496
-214,366
-92% -$626K ﹤0.01% 3139
2020
Q3 		$584K Buy
232,862
+178,717
+330% +$1.57M ﹤0.01% 1534
2020
Q2 		$735K Buy
54,145
+19,275
+55% +$199K 0.01% 1718
2020
Q1 		$264K Buy
34,870
+9,734
+39% +$75.7K ﹤0.01% 2322
2019
Q4 		$159K Buy
25,136
+10,674
+74% +$50.7K ﹤0.01% 2646
2019
Q3 		$57K Buy
+14,462
New +$62K ﹤0.01% 2799
2019
Q2 		– Sell
-26,797
Closed -$219K – 3046
2019
Q1 		$219K Sell
26,797
-52,227
-66% -$358K ﹤0.01% 2498
2018
Q4 		$437K Sell
79,024
-605
-0.8% -$4.73K ﹤0.01% 1957
2018
Q3 		$703K Buy
+79,629
New +$712K 0.01% 1937
2017
Q4 		– Sell
-8,650
Closed -$170K – 3155
2017
Q3 		$170K Sell
8,650
-534
-6% -$8.21K ﹤0.01% 2718
2017
Q2 		$132K Buy
+9,184
New +$116K ﹤0.01% 2723
2017
Q1 		– Sell
-14,852
Closed -$155K – 3251
2016
Q4 		$155K Buy
+14,852
New +$128K ﹤0.01% 2546
2016
Q2 		– Sell
-10,096
Closed -$91K – 2579
2016
Q1 		$91K Buy
+10,096
New +$81.9K ﹤0.01% 2648

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

SG Americas Securities's AKBA Position: Q1 2026 in Review

SG Americas Securities reduced its Akebia Therapeutics (AKBA) stake by 58% in Q1 2026, selling an estimated $138K and leaving 73,069 shares worth $102K. The position accounts for ﹤0.01% of the portfolio, ranked #2929.

SG Americas Securities first reported a position in AKBA in Q1 2016 and has held it in 24 quarters since. The position peaked at $735K in Q2 2020. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • SG Americas Securities held 73,069 shares of Akebia Therapeutics worth $102K as of Q1 2026.
  • SG Americas Securities sold 100,432 Akebia Therapeutics shares in Q1 2026, an estimated $138K.
  • Akebia Therapeutics made up ﹤0.01% of SG Americas Securities's portfolio in Q1 2026, its #2929 holding.
  • SG Americas Securities first reported a position in Akebia Therapeutics in Q1 2016 and has held it in 24 quarters since.
  • SG Americas Securities's Akebia Therapeutics position peaked at $735K in Q2 2020.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on SG Americas Securities's 13F filing for Q1 2026, filed 16 Apr 2026.